These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26994751)

  • 1. Conversion to mTOR-inhibitors with calcineurin inhibitor elimination or minimization reduces urinary polyomavirus BK load in kidney transplant recipients.
    Yen CL; Tian YC; Wu HH; Weng CH; Chen YC; Tu KH; Liu SH; Lee CC; Lai PC; Fang JT; Hung CC; Yang CW; Li YJ
    J Formos Med Assoc; 2016 Jul; 115(7):539-46. PubMed ID: 26994751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience.
    Moscarelli L; Caroti L; Antognoli G; Zanazzi M; Di Maria L; Carta P; Minetti E
    Clin Transplant; 2013; 27(4):546-54. PubMed ID: 23758330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate Mofetil Withdrawal With Conversion to Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients.
    Wojciechowski D; Chandran S; Webber A; Hirose R; Vincenti F
    Transplant Proc; 2017 Oct; 49(8):1773-1778. PubMed ID: 28923623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors influencing viral clearing and renal function during polyomavirus BK-associated nephropathy after renal transplantation.
    Schwarz A; Linnenweber-Held S; Heim A; Bröcker V; Rieck D; Framke T; Raggub L; Haller H
    Transplantation; 2012 Aug; 94(4):396-402. PubMed ID: 22836134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative analysis of clinical outcomes between conversion to mTOR inhibitor and calcineurin inhibitor reduction in managing BK viremia among kidney transplant patients.
    Cho A; Park S; Han A; Ha J; Park JB; Lee KW; Min S
    Sci Rep; 2024 Jun; 14(1):12855. PubMed ID: 38834615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients.
    Tohme FA; Kalil RS; Thomas CP
    Transpl Infect Dis; 2015 Feb; 17(1):66-72. PubMed ID: 25582442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian target of rapamycin signal inhibitors could play a role in the treatment of BK polyomavirus nephritis in renal allograft recipients.
    Sánchez Fructuoso AI; Calvo N; Perez-Flores I; Valero R; Rodríguez-Sánchez B; García de Viedma D; Muñoz P; Barrientos A
    Transpl Infect Dis; 2011 Dec; 13(6):584-91. PubMed ID: 21585634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of BK polyomavirus infection and association with renal dysfunction in pediatric heart transplant recipients.
    Ducharme-Smith A; Katz BZ; Bobrowski AE; Backer CL; Rychlik K; Pahl E
    J Heart Lung Transplant; 2015 Feb; 34(2):222-6. PubMed ID: 25540880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of BK polyomavirus infection after kidney transplantation is independent of type of immunosuppressive therapy.
    Radtke J; Dietze N; Fischer L; Achilles EG; Li J; Scheidat S; Thaiss F; Nashan B; Koch M
    Transpl Infect Dis; 2016 Dec; 18(6):850-855. PubMed ID: 27639176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observations on the use of cidofovir for BK virus infection in renal transplantation.
    Kuten SA; Patel SJ; Knight RJ; Gaber LW; DeVos JM; Gaber AO
    Transpl Infect Dis; 2014 Dec; 16(6):975-83. PubMed ID: 25412701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
    Mallat SG; Tanios BY; Itani HS; Lotfi T; McMullan C; Gabardi S; Akl EA; Azzi JR
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1321-1336. PubMed ID: 28576905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyomavirus infection in pediatric renal transplant recipients: evaluation using a quantitative real-time PCR technique.
    Herman J; Van Ranst M; Snoeck R; Beuselinck K; Lerut E; Van Damme-Lombaerts R
    Pediatr Transplant; 2004 Oct; 8(5):485-92. PubMed ID: 15367285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary exosomal viral microRNA as a marker of BK virus nephropathy in kidney transplant recipients.
    Kim MH; Lee YH; Seo JW; Moon H; Kim JS; Kim YG; Jeong KH; Moon JY; Lee TW; Ihm CG; Kim CD; Park JB; Chung BH; Kim YH; Lee SH
    PLoS One; 2017; 12(12):e0190068. PubMed ID: 29267352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen.
    Suwelack B; Malyar V; Koch M; Sester M; Sommerer C
    Transplant Rev (Orlando); 2012 Jul; 26(3):201-11. PubMed ID: 21940156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated heart and liver transplant recipients are at low risk for polyomavirus BKV nephropathy.
    Puliyanda DP; Amet N; Dhawan A; Hilo L; Radha RK; Bunnapradist S; Czer L; Martin P; Jordan S; Toyoda M
    Clin Transplant; 2006; 20(3):289-94. PubMed ID: 16824143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BK virus nephropathy in renal transplant recipients in Kuwait: a preliminary report.
    Nampoory MR; Johny KV; Pacsa A; Nair PM; Said T; Halim MA; Francis I; Samhan M; Mousawi M; Dalawi A; Szucs G; Al-Nakib W
    Transplant Proc; 2005 Sep; 37(7):3048-50. PubMed ID: 16213300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Factors of BK Virus Development in Kidney Transplant Recipients and the Effect of Low-Dose Tacrolimus Plus Everolimus on Clinical Outcomes.
    Yilmaz VT; Kisaoglu A; Avanaz A; Dandin O; Ozel D; Mutlu D; Akkaya B; Aydinli B; Kocak H
    Exp Clin Transplant; 2023 Sep; 21(9):727-734. PubMed ID: 37885288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different patterns of BK and JC polyomavirus reactivation following renal transplantation.
    Saundh BK; Tibble S; Baker R; Sasnauskas K; Harris M; Hale A
    J Clin Pathol; 2010 Aug; 63(8):714-8. PubMed ID: 20702473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States.
    Gupta G; Kuppachi S; Kalil RS; Buck CB; Lynch CF; Engels EA
    Am J Transplant; 2018 Jan; 18(1):245-252. PubMed ID: 28980390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of polyomavirus BK replication and impact of preemptive immunosuppression reduction in renal-transplant recipients in China: a 5-year single-center analysis.
    Huang G; Wang CX; Zhang L; Fei JG; Deng SX; Qiu J; Li J; Chen GD; Fu Q; Chen LZ
    Diagn Microbiol Infect Dis; 2015 Jan; 81(1):21-6. PubMed ID: 25445121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.